Denise Cerqueira Paranaguá Vezozzo

Denise Cerqueira Paranaguá Vezozzo

Auto-generated profile, based on publicly available information

Denise Cerqueira Paranaguá Vezozzo

Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Maturitas
Verified
Journal Article
Closed access
CRCristiana Maria Rocha Fidalgo dos Reis
Cristiana Maria Rocha Fidalgo dos Reis
NMNilson Roberto de Melo
Nilson Roberto de Melo
EMEduardo Souza Meirelles
Eduardo Souza Meirelles
DVDenise Paranaguá Vezozzo
Denise Paranaguá Vezozzo
AHAlfredo Halpern
Alfredo Halpern

4 September 2009 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
ACA.L. Chagas
A.L. Chagas
LKL.O.O. Kikuchi
L.O.O. Kikuchi
COC.P.M.S. Oliveira
C.P.M.S. Oliveira
DVD.C.P. Vezozzo
D.C.P. Vezozzo
EME.S. Mello
E.S. Mello
FCF.J. Carrilho
F.J. Carrilho
Non-alcoholic steatohepatitis (NASH) has been associated with hepatocellular carcinoma (HCC) often arising in histologically advanced disease when steatohepatitis is not active (cryptogenic cirrhosis). Our objective was to characterize patients with HCC and active, histologically defined steatohepatitis. Among 394 patients with HCC detected by ultrasound imaging over 8 years and staged by the Barcelona Clinic Liver Cancer (BCLC) criteria, we identified 7 cases (1.7%) with HCC occurring in the setting of active biopsy-proven NASH. All were negative for other liver diseases such as hepatitis C, hepatitis B, autoimmune hepatitis, Wilson disease, and hemochromatosis. The patients (4 males and 3 females, age 63 +/- 13 years) were either overweight (4) or obese (3); 57% were diabetic and 28.5% had dyslipidemia. Cirrhosis was present in 6 of 7 patients, but 1 patient had well-differentiated HCC in the setting of NASH without cirrhosis (fibrosis stage 1) based on repeated liver biopsies, the absence of portal hypertension by clinical and radiographic evaluations and by direct surgical inspection. Among the cirrhotic patients, 71.4% were clinically staged as Child A and 14.2% as Child B. Tumor size ranged from 1.0 to 5.2 cm and 5 of 7 patients were classified as early stage; 46% of all nodules were hyper-echoic and 57% were <3 cm. HCC was well differentiated in 1/6 and moderately differentiated in 5/6. Alpha-fetoprotein was <100 ng/mL in all patients. HCC in patients with active steatohepatitis is often multifocal, may precede clinically advanced disease and occurs without diagnostic levels of alpha-fetoprotein. Importantly, HCC may occur in NASH in the absence of cirrhosis. More aggressive screening of NASH patients may be warranted.

1 July 2014 in Annals of Hepatology
Verified
Journal Article
Open access
DPDenise C. Paranaguá-Vezozzo
Denise C. Paranaguá-Vezozzo
SOSuzane K. Ono
Suzane K. Ono
MAMónica V. Alvarado-Mora
Mónica V. Alvarado-Mora
AFAlberto Q. Farias
Alberto Q. Farias
MCMarione Cunha-Silva
Marione Cunha-Silva
FCFlair José Carrilho
Flair José Carrilho
The lack of information about hepatocellular carcinoma (HCC) in Brazil weakens health policy in preventing deaths from the illness. The aim of this study was to establish the cumulative incidence and the risk factors for hepatocellular carcinoma development in patients under a surveillance program. 884 patients with compensated cirrhosis were prospectively followed up for at least five years, from August 1998 until August 2008, with at least one annual ultrasonography liver examination and serum alpha fetoprotein (AFP) measurement. Among 884 patients, 72 (8.1%) developed a tumor with a median follow up of 21.4 months. In the hepatocellular carcinoma group, hepatitis C virus infection was the major etiological factor (65.3%), 56.9% (41/72) were male and the mean average age was 57 ± 10 years. The annual incidence of hepatocellular carcinoma was 2.9%. 79.2% (57/72) of HCCs were detected within Milan Criteria, and the mean survival time was 52.3 months, significantly higher than for those outside Milan, with a mean time of 40.6 months (p = 0.0003). The annual incidence of HCC among this large series of Brazilian cirrhotic patients was around 2.9% with a detection rate of 8.1%, or a cumulative incidence rate over five years of 14.3%. The three variables related to HCC risk were low serum albumin [HR: 0.518 (0.46-0.78)], high AFP > 20 ng/mL [HR: 3.16 (1.86-5.38)], and ethnicity (Brazilian-East Asian descendants vs. other mixed Brazilian ethnicities) [HR: 2.86 (1.48-5.53)].

1 September 1993 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MSMaria E R Silva
Maria E R Silva
DVDenise P Vezozzo
Denise P Vezozzo
MUMileni J M Ursich
Mileni J M Ursich
DRDalva M Rocha
Dalva M Rocha
GCGiovanni G Cerri
Giovanni G Cerri
BWBernardo L Wajchenberg
Bernardo L Wajchenberg
Objective— To evaluate the relationship between the type and duration of diabetes and pancreas size by ultrasonography. Research Design and Methods— Pancreas images of 40 IDDM and 36 NIDDM patients with 0.3–34 yr of disease were compared with those of 60 normal healthy control subjects. Results— The diameters ± SD of the head, body, and tail of the pancreas in IDDM patients (1.9 ± 0.3; 0.9 ± 0.2; and 1.4 ± 0.2 cm, respectively) were smaller than in NIDDM patients (2.7 ± 0.4; 1.2 ± 0.3; and 1.8 ± 0.4 cm, respectively) and control group subjects (2.4 ± 0.4; 1.1 ± 0.3; and 1.8 ± 0.4 cm, respectively). The pancreatic shrinkage in IDDM patients was clearly evident after 10 yr of the disease. NIDDM patients and control subjects had similar pancreatic dimensions, except for a greater body thickness in NIDDM patients with >10 yr of disease (1.2 ± 0.4 vs. 1.1 ± 0.3 cm). These results were not related to differences in age, sex, and body size. Pancreas image was hypoechogenic in 72.5% of IDDM patients and hyperechogenic in 83.3% of NIDDM patients. Conclusions— Smaller pancreases in IDDM patients in comparison with NIDDM patients and control subjects were clearly demonstrated only after 10 yr of disease. Patients with NIDDM were not affected by pancreatic dimensions, except for a greater body thickness after 10 yr of disease. Pancreatic echogenicity increased with age.

1 February 2009 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
LKLuciana O.O. Kikuchi
Luciana O.O. Kikuchi
DPDenise C. Paranaguá-Vezozzo
Denise C. Paranaguá-Vezozzo
ACAline L. Chagas
Aline L. Chagas
EMEvandro S. Mello
Evandro S. Mello
VAVenancio A.F. Alves
Venancio A.F. Alves
FCFlair J. Carrilho
Flair J. Carrilho
The aims of this study were to analyze the overall survival of patients with cirrhosis and small hepatocellular carcinoma (HCC) and identify independent pretreatment predictors of survival in Brazil. Between 1998 and 2003, 74 patients with cirrhosis and small HCC were evaluated. Predictors of survival were identified using the Kaplan-Meier survival curves and the Cox model. The overall survival rates were 80%, 41%, and 17% at 12, 36, and 60 months, respectively. The mean length of follow-up after HCC diagnosis was 23 months (median 22 mo, range: 1 to 86 mo) for the entire group. Univariate analysis showed that model for endstage liver disease (MELD) score (P=0.016), Child-Pugh classification (P=0.007), alpha-fetoprotein level (P=0.006), number of nodules (P=0.041), tumor diameter (P=0.009), and vascular invasion (P20 mm (relative risk=2.14, confidence interval 95%=1.07-4.2, P=0.030) as independent predictors of decreased survival. Treatment of HCC was related to increased overall survival. Identification of HCC smaller than 20 mm is associated with longer survival. Presence of vascular invasion, even in small tumors, maybe associated with poor prognosis. Treatment of small tumors of up to 20 mm diameter is related to increased survival.

26 June 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JNJeronimo A Nogueira
Jeronimo A Nogueira
SOSuzane K Ono-Nita
Suzane K Ono-Nita
MNMarcelo E Nita
Marcelo E Nita
MSMarcelo Mt de Souza
Marcelo Mt de Souza
ECEliane P Do Carmo
Eliane P Do Carmo
VAVenancio Af Alves
Venancio Af Alves
Background: Ser-249 TP53 mutation (249Ser) is a molecular evidence for aflatoxin-related carcinogenesis in Hepatocellular Carcinoma (HCC) and it is frequent in some African and Asian regions, but it is unusual in Western countries. HBV has been claimed to add a synergic effect on genesis of this particular mutation with aflatoxin. The aim of this study was to investigate the frequency of 249Ser mutation in HCC from patients in Brazil. Methods: We studied 74 HCC formalin fixed paraffin blocks samples of patients whom underwent surgical resection in Brazil. 249Ser mutation was analyzed by RFLP and DNA sequencing. HBV DNA presence was determined by Real-Time PCR. Results: 249Ser mutation was found in 21/74 (28%) samples while HBV DNA was detected in 13/74 (16%). 249Ser mutation was detected in 21/74 samples by RFLP assay, of which 14 were confirmed by 249Ser mutant-specific PCR, and 12 by nucleic acid sequencing. All HCC cases with p53-249ser mutation displayed also wild-type p53 sequences. Poorly differentiated HCC was more likely to have 249Ser mutation (OR = 2.415, 95% CI = 1.001 – 5.824, p = 0.05). The mean size of 249Ser HCC tumor was 9.4 cm versus 5.5 cm on wild type HCC (p = 0.012). HBV DNA detection was not related to 249Ser mutation. Conclusion: Our results indicate that 249Ser mutation is a HCC important factor of carcinogenesis in Brazil and it is associated to large and poorly differentiated tumors.